GREGORY PAPA: Open Payments
NPI 1730242397 · NEW CASTLE, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,664 in 171 payments from 24 companies in 2025. Trend: 2023 $4,248 · 2024 $4,146 · 2025 $3,664
Food & beverage: $3,664
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $570 |
| Axsome Therapeutics, Inc. | 28 | $472 |
| ABBVIE INC. | 20 | $427 |
| Novo Nordisk Inc | 15 | $405 |
| PFIZER INC. | 28 | $341 |
| Corcept Therapeutics | 16 | $312 |
| GlaxoSmithKline, LLC. | 12 | $275 |
| Alkermes, Inc. | 7 | $151 |
| Neurocrine BioSciences, Inc. | 1 | $133 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $76 |
Products named: BREZTRI, Korlym, QULIPTA, Sunosi, FARXIGA, Auvelity, Rybelsus, TRELEGY ELLIPTA.
Industry payments across DE — which companies pay providers there.
